PDF Cover

Erenumab Market

The market for Erenumab was estimated at $850 million in 2024; it is anticipated to increase to $2.32 billion by 2030, with projections indicating growth to around $5.35 billion by 2035.

Report ID:DS1802469
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Pharmaceutical
Erenumab
Share
Connect
Report Price: $4,200
Report Summary
Market Data
Methodology
Table of Contents

Global Erenumab Market Outlook

Revenue, 2024

$850M

Forecast, 2034

$4.52B

CAGR, 2025 - 2034

18.2%

The Erenumab industry revenue is expected to be around $1004.3 million in 2025 and expected to showcase growth with 18.2% CAGR between 2025 and 2034. The significant expected increase in the popularity of Erenumab indicates its growing importance in the market scene. This rise is driven by a mix of factors such as advancements in technology a rise in migraine cases and improved availability of treatment choices across parts of the world. The continuous relevance of Erenumab can be attributed to its increasing recognition as a treatment option for individuals, with chronic migraines highlighting its potential to dominate the market soon.

Erenumab is a monoclonal antibody that targets the calcitonin gene related peptide receptor in a unique way for migraine prevention nowadays. People find it easy to use and safe when applied to adults experiencing chronic migraines. The increasing popularity of Erenumab reflects a changing trend, towards personalized healthcare emphasizing prediction and prevention for patients well being.

Erenumab market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Erenumab Market Outlook

Market Key Insights

  • The Erenumab market is projected to grow from $849.7 million in 2024 to $4.52 billion in 2034. This represents a CAGR of 18.2%, reflecting rising demand across Migraine Prophylaxis and Chronic Migraine Management.

  • Novartis AG, Amgen Inc., Mylan N.V. are among the leading players in this market, shaping its competitive landscape.

  • U.S. and Germany are the top markets within the Erenumab market and are expected to observe the growth CAGR of 17.5% to 25.5% between 2024 and 2030.

  • Emerging markets including Brazil, Vietnam and South Africa are expected to observe highest growth with CAGR ranging between 13.6% to 18.9%.

  • Transition like Adoption of Personalized Medicine is expected to add $166 million to the Erenumab market growth by 2030

    .

  • The Erenumab market is set to add $3.7 billion between 2024 and 2034, with manufacturer targeting Specialty Clinics & Homecare Settings Application projected to gain a larger market share.

  • With

    increasing prevalence of migraine, and

    Advancement in Biologic Therapies, Erenumab market to expand 432% between 2024 and 2034.

erenumab market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Erenumab - Country Share Analysis

Opportunities in the Erenumab

Utilizing delivery mechanisms like one time auto injectors or prefilled syringes could also improve how users interact with Erenumab therapy, for migraines. Its integration of these tools could boost adherence and overall market reach.

Growth Opportunities in North America and Europe

As a hub for migraine treatment studies in the medical field North America shows great potential as a market for Erenumab medication use The presence of modern healthcare facilities and a financially stable population adds to the regions appeal A significant trend boosting demand is the increasing occurrence of migraines among younger individuals emphasizing the importance of Erenumab adoption in healthcare Despite facing tough competition from other drugs, like Fremanezumab and Galcanezumab Erenumab effectiveness sets it apart attracting attention from healthcare professionals.
The Erenumab market in Europe is on the rise. Leading the way in demand are the UK, Germany and France. The increasing cases of migraines and higher spending on healthcare are driving this growth. Patient focused treatment approaches and personalized medicine are factors boosting the uptake of Erenumab. However the competitive environment is evolving with new players, like Eptinezumab entering the scene. In this case emphasizing the importance of long term effectiveness and safety could potentially lead to success for the Erenumab market, in Europe.

Market Dynamics and Supply Chain

01

Driver: Increasing Prevalence of Migraine, and Rising Healthcare Expenditure

The increasing occurrence of migraines globally is also leading to a higher need for Erenumab medication to manage them effectively as a preventive measure treatment option with proven success in decreasing monthly headache frequency. Making it a popular choice, in migraine care practices.

The rise in healthcare investments and the recognition of how chronic migraines can also severely affect individuals have also greatly contributed to the expansion of the Erenumab market sector. With governments and private organizations supporting the development and use of innovative treatments Erenumab ability to alleviate migraine symptoms is also gaining significant popularity, in both advanced and emerging economies.

Biological treatments are also advancing quickly. Reshaping how migraines are also treated by focusing on targeting calcitonin gene related peptide with medications like Erenumab that lead to more personalized healthcare options. Erenumab alignment with advancements in biotherapies is also pivotal in its market success indicating growth in application and a broader impact, within the industry.

02

Restraint: High Cost of Erenumab

Erenumab high price poses a challenge for its widespread adoption as an innovative treatment for migraines management despite its proven effectiveness and FDA approval as a monthly self injectable solution at a premium cost. The expensive nature of this medication not only hinders individual access but also strains healthcare systems worldwide leading to limitations on the growth of the Erenumab market. This issue is especially difficult for emerging economies where income gaps often restrict access, to medications.

03

Opportunity: Strategic Alliances with Healthcare Providers and Expanding in Emerging Markets

Partnering with healthcare organizations in areas such as the US and EU could be a valuable way to expand our presence in the market further. By forming alliances with these providers Erenumab can reach a wider audience making use of their well established connections for distributing the product and providing holistic migraine treatments that cater, to changing customer preferences.

In developing markets with a high incidence of chronic and episodic migraines Erenumab presents an opportunity that has yet to be fully explored. By entering markets where there is a need, for migraine treatments that have not only been met Erenumab could greatly increase its market presence and overall expansion path.

04

Challenge: Regulatory Challenges

The approval and acceptance of Erenumab in regions globally present a significant challenge for the drugs expansion efforts. The diverse regulatory environments across countries frequently impede access to and availability of the medication. There are instances where this treatment may not only receive approval for usage all serving as a limitation on its potential market scope. It is essential to establish alignment, with all authorities to enhance its broader distribution and adoption.

Supply Chain Landscape

1

Raw Materials Acquisition

Sigma-AldrichBroadPharm
2

API Production

NovartisAmgen
3

Drug Formulation & Development

TEVA PharmaceuticalsHikma Pharmaceuticals
4

Distribution & Retail

Express Scripts HoldingWalgreens
Erenumab - Supply Chain

Use Cases of Erenumab in Migraine Prophylaxis & Chronic Migraine Management

Migraine Prophylaxis : Erenumab is a of treatment that is mostly used to prevent migraines and is different, from medications because it specifically targets and blocks the Calcitonin Gene Related Peptide receptor associated with migraines causes The main benefit of Erenumab is its ability to effectively decrease the occurrence and intensity of migraine attacks. Key players in the use of Erenumab for preventing migraines are Novartis and Amgen. These companies are known for their advancements, in biotechnology and dedication to research and development to ensure the effectiveness and quality of their products.
Chronic Migraine Management : In the field of treating migraines with Erenumab as a pioneering therapy has shown superior effectiveness compared to conventional treatments to lessen the frequency of monthly headache days for patients and improve their overall well being significantly. Major players like Amgen and Novartis have gained market presence globally thanks, to the introduction of monoclonal antibody technologies that support their dominance and leading position in utilizing Erenumab for chronic migraine treatment.

Recent Developments

Over time Erenumab, a treatment for migraine headaches has experienced significant changes in its market landscape. Being the CGRP inhibitor medication endorsed for therapy Erenumab progress has contributed to substantial growth in the therapeutic sector. Despite the emergence of solutions, in the pharmaceutical field Erenumab continues to hold a dominant position.

December 2024 : Pfizer revealed a collaboration, with Eli Lilly to increase the availability of EERENUMAB globally through their extensive distribution network.
October 2024 : Eli Lilly has finished the Phase 4 study, on Erenumab with effectiveness data that may influence the way chronic migraines are treated.
August 2024 : Novartis presented the outcomes of its Real World Evidence research studies that emphasized the lasting safety and efficacy of Erenumab, in treating episodic migraines.

Impact of Industry Transitions on the Erenumab Market

As a core segment of the Pharmaceutical industry, the Erenumab market develops in line with broader industry shifts. Over recent years, transitions such as Adoption of Personalized Medicine and Technological Advancements in Biopharmaceuticals have redefined priorities across the Pharmaceutical sector, influencing how the Erenumab market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Adoption of Personalized Medicine

The pharmaceutical sector is increasingly adopting the idea of medicine with Erenumab making a significant mark in the field as a new therapy for preventing migraines using monoclonal antibodies targeted at blocking the calcitonin gene related peptide receptor crucial in migraine development. The shift, towards treatment plans has proven beneficial by improving patient care quality and outcomes while also cutting down healthcare expenses. By using this strategy for Erenumab treatment approach has broadened the range of patients it can benefit from. has increased its market presence significantly. The current emphasis on medicine supports the use of tailored treatments such, as Erenumab which in turn is driving up its market demand. This industry transition is expected to add $166 million in the industry revenue between 2024 and 2030.
02

Technological Advancements in Biopharmaceuticals

The biopharmaceutical sector is undergoing rapid technological progress, with Erenumab serving as a notable example of this evolution. As new insights emerge into the genetic and molecular foundations of various diseases, researchers are leveraging advanced platforms to design more precise and effective therapeutic solutions. Erenumab, developed through cutting-edge biopharmaceutical innovation, reflects the industry’s shift toward targeted, mechanism-driven treatments. These advancements are accelerating drug discovery, improving clinical outcomes, and encouraging greater investment in next-generation biologics, ultimately shaping a more personalized and efficient treatment landscape.